Thu, Jul 24, 2014, 10:37 AM EDT - U.S. Markets close in 5 hrs 23 mins

Recent

% | $
Click the to save as a favorite.

Manulife Financial Corporation Message Board

lws2000 196 posts  |  Last Activity: 20 minutes ago Member since: Nov 21, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • PREVIOUS: "Mayo has published the "good news" about Imetelstat, but the market still has no clue. This is a mystery. Seeking Alpha notes, that this stock is about to explode. There can be no other outcome. $10 sometime between next week and the next ASH conference. I don't know exactly when, but it is coming."

    The "Mystery" is that everyone (in science & medical community that cares) knows that Imetelstat is a "miracle drug" and Mayo is now shouting it from the roof tops. So why doesn't the general market get it? The answer seems to be in the Mayo-FDA-Geron arrangements and contracts, since no one seems to believe that the Mayo trials and results are fraudulent. Mayo is in control, and Geron's hands are tied (by Mayo & the FDA). In addition, we now have the Yale input (p21, p53, telomeres, etc.). Great things are coming, but, so far, the market does not get it.

  • Mayo has published the "good news" about Imetelstat, but the market still has no clue. This is a mystery. Seeking Alpha notes, that this stock is about to explode. There can be no other outcome. $10 sometime between next week and the next ASH conference. I don't know exactly when, but it is coming.

  • How can we get this information to Yahoo (about bashers and good information)?

    PREVIOUS: Miracle Drug, P21, Mystery, Mayo

    With this new format, it will be difficult to have a continuing conversation, that doesn't get lost in the bashing jimberish.

    PREVIOUS: "All looks good. Researchers (Yale) uncover new cancer cell vulnerability (Fri, 07/18/2014)--telomeres & p21. Geron has a working, "miracle drug" and a "great pipeline". It is a "Mystery" why this stock isn't soaring with so much proven and so much potential."

    Mayo is the defining entity here. They have the MF patients and the trials that have been successful, and have the complete trust of the FDA. If all is kosher, this should be a $10 stock right now. The Mayo-Geron contract is the major mystery, with Mayo in control, and Geron doing what they are told to do (under the contract). Big pharma has to be interested."

  • With this new format, it will be difficult to have a continuing conversation, that doesn't get lost in the bashing jimberish.

    PREVIOUS: "All looks good. Researchers (Yale) uncover new cancer cell vulnerability (Fri, 07/18/2014)--telomeres & p21. Geron has a working, "miracle drug" and a "great pipeline". It is a "Mystery" why this stock isn't soaring with so much proven and so much potential."

    Mayo is the defining entity here. They have the MF patients and the trials that have been successful, and have the complete trust of the FDA. If all is kosher, this should be a $10 stock right now. The Mayo-Geron contract is the major mystery, with Mayo in control, and Geron doing what they are told to do (under the contract). Big pharma has to be interested.

  • I think (as others have put forward) that the "Mystery" is in the arrangements that Mayo has with Geron. Imelelstat had known potential from the animal studies, but so many drugs that work for animals fail the human test. Imetelstat appears to be the exception. To conduct the human trials, I believe that Mayo required very strict control. Imetelstat will move along on Mayo's schedule, with Mayo's plan, IMO. Geron is following the Mayo-Geron contract, which investors have not seen.

    The FDA would rather deal with Mayo, who has all of the MF trials and patients. All looks good, but Mayo & the FDA are being very cautious. That is time consuming, but Mayo & the FDA must have their reasons. Geron will eventually benefit, but (when?) is everyone's question.

  • All looks good. Researchers (Yale) uncover new cancer cell vulnerability (Fri, 07/18/2014)--telomeres & p21. Geron has a working, "miracle drug" and a "great pipeline". It is a "Mystery" why this stock isn't soaring with so much proven and so much potential.

  • Xilinx sell-off brings 'great' entry point, says FBR Capital
    FBR Capital says the post-earnings sell-off in shares of Xilinx provides a "great" entry point into the name. FBR lowered its price target for Xilinx to $62 from $65 and keeps an Outperform rating on the stock. Shares were downgraded this morning at three firms.

  • lws2000 lws2000 Jul 22, 2014 10:40 AM Flag

    Mayo knows what it is doing. The potential for telomere research and breakthroughs is almost infinite.

  • Imetelstat and Yale: New Combination Opportunities for Imetelstat

    Interesting:

    Yale School of Medicine and Yale Cancer Center researchers have uncovered a genetic vulnerability of cancer cells that express telomerase—an enzyme that drives their unchecked growth—and showed that telomerase-expressing cells depend upon a gene named p21 for their survival.

    Authors found that simultaneous inhibition of both telomerase and p21 inhibited tumor growth in mice. The telomerase enzyme is overexpressed in over 90% of human cancers, but not in normal cells, and expression of telomerase is necessary to initiate and promote cancer growth. In this study, the Yale team, led by first author Romi Gupta and corresponding author Narendra Wajapeyee of the Dept. of Pathology, showed how new pharmacological drug combinations can be applied to simultaneously target both telomerase and p21 to induce cell death in telomerase-expressing cancer cells.

    Finally, the authors also showed that their approach is also applicable for p53 mutant cancers if telomerase and p21 inhibition is combined with pharmacological restoration of p53 tumor suppressor activity. The study, which could open doors to novel therapies for telomerase inhibition, appears in the Proceedings of the National Academy of Sciences.

    Source: Yale Univ.

  • Reply to

    GERON MGMT MOVES TOO SLOWLY...

    by micaiah2004 Jul 21, 2014 7:07 PM
    lws2000 lws2000 Jul 21, 2014 9:14 PM Flag

    This is Mayo's game. Mayo took on the Imetelstat project with a certain level of exclusivity, since the outcome was highly speculative. Perhaps 1 in 20 of these drugs work out at all. The level of success here is rare. Mayo will dictate where and when this drug is used, at least for now. That is why Geron is so passive.

  • lws2000 lws2000 Jul 21, 2014 5:44 PM Flag

    Interesting:

    Yale School of Medicine and Yale Cancer Center researchers have uncovered a genetic vulnerability of cancer cells that express telomerase—an enzyme that drives their unchecked growth—and showed that telomerase-expressing cells depend upon a gene named p21 for their survival.

    Authors found that simultaneous inhibition of both telomerase and p21 inhibited tumor growth in mice. The telomerase enzyme is overexpressed in over 90% of human cancers, but not in normal cells, and expression of telomerase is necessary to initiate and promote cancer growth. In this study, the Yale team, led by first author Romi Gupta and corresponding author Narendra Wajapeyee of the Dept. of Pathology, showed how new pharmacological drug combinations can be applied to simultaneously target both telomerase and p21 to induce cell death in telomerase-expressing cancer cells.

    Finally, the authors also showed that their approach is also applicable for p53 mutant cancers if telomerase and p21 inhibition is combined with pharmacological restoration of p53 tumor suppressor activity. The study, which could open doors to novel therapies for telomerase inhibition, appears in the Proceedings of the National Academy of Sciences.

    Source: Yale Univ.

  • Reply to

    No Hidden Bad News About Imetelstat

    by lws2000 Jul 17, 2014 10:19 AM
    lws2000 lws2000 Jul 18, 2014 7:30 PM Flag

    I said, "Nothing is further from the truth, as Mayo (USA #1) continues full support". I have full confidence in Mayo (their data, patients and trials). As long as Mayo is upbeat, I will continue my long investment in Geron. Either there is something that we don't know that is devastating (don't think so), or as you say Imetelstat is likely a medical marvel. Actually, I am investing in Mayo Clinic's reputation. Geron is a bit mysterious, with some questionable history. Mayo, IMO, will keep Geron reasonably honest.

  • Reply to

    No Hidden Bad News About Imetelstat

    by lws2000 Jul 17, 2014 10:19 AM
    lws2000 lws2000 Jul 17, 2014 11:30 AM Flag

    Remissions & Cures with telomere control

  • The way Geron stock is acting one would think that announcements of Imelestat's failures are imminent. Nothing is further from the truth, as Mayo (USA #1) continues full support.

  • lws2000 lws2000 Jul 16, 2014 11:55 AM Flag

    My guess is that Geron will close over $3.00 on Monday.

  • Reply to

    This Was A Nice Beat

    by vincent90157 Jul 15, 2014 6:14 PM
    lws2000 lws2000 Jul 15, 2014 6:20 PM Flag

    Intel is back and will catch up in mobile in 2015. $50 by the end of the year.

    Sentiment: Strong Buy

  • lws2000 lws2000 Jul 15, 2014 3:37 PM Flag

    Yellen's remarks were not aimed at Geron (way underpriced), but pulled it down just the same. It may take a few days to get over $3.00. The trend is upward, but the road is bumping with "trolls" along the way. The Geron-Mayo marriage is in good shape.

  • lws2000 lws2000 Jul 15, 2014 2:22 PM Flag

    Jesus wanted equally and a fair-shake for the locals (money changers, etc.), and was anti-Roman (the occupying military force). This cost him his life on earth, but brought him immortality.

  • Geron is not over priced, but temporarily hit by Yellen's comments. Some small biotech companies and some social media companies are in bubble territory, according to Yellen. At this point in time, Geron is still in the $2.80 to $3.00 channel, as dictated by money managers. Mayo's good medicine and science will dominate soon (see Mayo's new brochure about Imetelstat). Stay with Geron, Mayo and breakthroughs around telomeres.

MFC
20.46+0.07(+0.34%)10:36 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.